| Chronic Lymphocytic Leukemia |
1 |
1 |
| Biologic Therapy |
0 |
0.9 |
| Acute Myeloblastic Leukemia |
0 |
0.99 |
| Antineoplastic Drug |
0 |
0.59 |
| Toxicology |
0 |
0.58 |
| Acute Leukemia |
0 |
0.53 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.53 |
| Cancer |
0 |
0.36 |
| Blood |
0 |
0.3 |
| Monoclonal Antibody |
0 |
0.3 |
| Non-Hodgkin Lymphoma (NHL) |
0 |
0.28 |
| Chemotherapy |
0 |
0.23 |
| Leukemia |
0 |
0.23 |
| Lymphoma |
0 |
0.23 |
| Refractory |
0 |
0.23 |
| Thrombocytopenia |
0 |
0.23 |
| Acute Lymphoblastic Leukemia |
0 |
0.21 |
| B-Cell Lymphoma |
0 |
0.21 |
| Follicular Lymphoma |
0 |
0.21 |
| Mantle Cell Lymphoma |
0 |
0.18 |
| Tumor Lysis Syndrome |
0 |
0.11 |
| Clinical Research |
0 |
0.08 |
| Hematological Disorders |
0 |
0.08 |
| Lymphocytes |
0 |
0.08 |
| Myelosuppression |
0 |
0.08 |
| Neoplasm |
0 |
0.08 |
| Plasma |
0 |
0.08 |
| Prognosis |
0 |
0.08 |
| Remission |
0 |
0.08 |
| Tumor |
0 |
0.08 |
| Myelofibrosis |
0 |
0.06 |